JP2024525780A5 - - Google Patents
Info
- Publication number
- JP2024525780A5 JP2024525780A5 JP2024501976A JP2024501976A JP2024525780A5 JP 2024525780 A5 JP2024525780 A5 JP 2024525780A5 JP 2024501976 A JP2024501976 A JP 2024501976A JP 2024501976 A JP2024501976 A JP 2024501976A JP 2024525780 A5 JP2024525780 A5 JP 2024525780A5
- Authority
- JP
- Japan
- Prior art keywords
- interleukin
- receptor
- inhibitor
- residue
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163221806P | 2021-07-14 | 2021-07-14 | |
| US63/221,806 | 2021-07-14 | ||
| PCT/US2022/037221 WO2023288028A2 (en) | 2021-07-14 | 2022-07-14 | Peptide inhibitors of interleukin-23 receptor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024525780A JP2024525780A (ja) | 2024-07-12 |
| JP2024525780A5 true JP2024525780A5 (https=) | 2025-07-24 |
Family
ID=84920532
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024501976A Pending JP2024525780A (ja) | 2021-07-14 | 2022-07-14 | インターロイキン－２３受容体のペプチド阻害剤 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240409598A1 (https=) |
| EP (1) | EP4370531A4 (https=) |
| JP (1) | JP2024525780A (https=) |
| KR (1) | KR20240034222A (https=) |
| CN (1) | CN117999274A (https=) |
| AU (1) | AU2022310354A1 (https=) |
| CA (1) | CA3226539A1 (https=) |
| MX (1) | MX2024000762A (https=) |
| TW (1) | TW202332683A (https=) |
| UY (1) | UY39856A (https=) |
| WO (1) | WO2023288028A2 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4091624A1 (en) | 2013-03-15 | 2022-11-23 | Protagonist Therapeutics, Inc. | Hepcidin analogues and uses thereof |
| HRP20211448T1 (hr) | 2014-05-16 | 2021-12-24 | Protagonist Therapeutics, Inc. | Alfa4beta7 integrin tioeter peptidni antagonisti |
| CN107206254B (zh) | 2014-07-17 | 2021-08-24 | 领导医疗有限公司 | 白细胞介素-23受体的口服肽抑制剂以及其治疗炎症性肠病的用途 |
| CA3089868A1 (en) | 2018-02-08 | 2019-08-15 | Protagonist Therapeutics, Inc. | Conjugated hepcidin mimetics |
| AU2021209086A1 (en) | 2020-01-15 | 2022-08-04 | Janssen Biotech, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| JP7397239B2 (ja) | 2020-11-20 | 2023-12-12 | ヤンセン ファーマシューティカ エヌ．ベー． | インターロイキン－２３受容体のペプチド阻害剤の組成物 |
| EP4370146A4 (en) | 2021-07-14 | 2025-05-21 | Janssen Biotech, Inc. | Lipidated peptide inhibitors of the interleukin-23 receptor |
| EP4652180A2 (en) * | 2023-01-16 | 2025-11-26 | Janssen Pharmaceutica NV | Peptide inhibitors of interleukin-23 receptor |
| US20240279281A1 (en) * | 2023-01-16 | 2024-08-22 | Janssen Pharmaceutica Nv | Peptide Inhibitors of Interleukin-23 Receptor |
| WO2024155553A1 (en) * | 2023-01-16 | 2024-07-25 | Janssen Pharmaceutica Nv | Lipidated peptide inhibitors of interleukin-23 receptor |
| IL322423A (en) * | 2023-01-31 | 2025-09-01 | Janssen Pharmaceutica Nv | Methods for preparing crystalline peptide inhibitors of the interleukin-23 receptor |
| CN120826233A (zh) * | 2023-03-03 | 2025-10-21 | 詹森药业有限公司 | 用于治疗银屑病的白介素-23受体拮抗剂肽 |
| EP4471048A1 (en) | 2023-06-01 | 2024-12-04 | Zealand Pharma A/S | Peptide inhibitors of interleukin-23 receptor |
| EP4471049A1 (en) | 2023-06-01 | 2024-12-04 | Zealand Pharma A/S | Peptide inhibitors of interleukin-23 receptor |
| CN121909205A (zh) | 2023-09-08 | 2026-04-21 | 赛诺菲 | 作为选择性il-23受体抑制剂的新型肽 |
| CN121794283A (zh) | 2023-09-08 | 2026-04-03 | 赛诺菲 | 作为选择性il-23受体抑制剂的新型肽 |
| WO2026013260A1 (en) | 2024-07-12 | 2026-01-15 | Zealand Pharma A/S | Peptide inhibitors of interleukin-23 receptor |
| WO2026026816A1 (zh) * | 2024-07-30 | 2026-02-05 | 西藏海思科制药有限公司 | 白介素-23受体的肽抑制剂及其用途 |
| WO2026041110A1 (zh) * | 2024-08-22 | 2026-02-26 | 上海瀚辰星泰医药科技有限公司 | 一种多肽化合物及其应用 |
| WO2026046292A1 (zh) * | 2024-08-28 | 2026-03-05 | 西藏海思科制药有限公司 | 白介素-23受体的肽抑制剂的药物组合物及其制备方法和用途 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9605027B2 (en) * | 2011-06-14 | 2017-03-28 | Medical Diagnostic Laboratories, Llc | Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof |
| CN107206254B (zh) * | 2014-07-17 | 2021-08-24 | 领导医疗有限公司 | 白细胞介素-23受体的口服肽抑制剂以及其治疗炎症性肠病的用途 |
| US10787490B2 (en) * | 2015-07-15 | 2020-09-29 | Protaganist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| MX384213B (es) * | 2015-07-15 | 2025-03-14 | Protagonist Therapeutics Inc | Inhibidores peptidicos del receptor de interleucina 23 y su uso para tratar enfermedades inflamatorias. |
| WO2018136646A1 (en) * | 2017-01-18 | 2018-07-26 | Protagonist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| WO2020014646A1 (en) * | 2018-07-12 | 2020-01-16 | Protagonist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| JP7534382B2 (ja) * | 2019-07-10 | 2024-08-14 | プロタゴニスト セラピューティクス， インコーポレイテッド | インターロイキン－２３受容体のペプチド阻害剤及び炎症性疾患を治療するためのその使用 |
| WO2021007433A1 (en) * | 2019-07-10 | 2021-01-14 | Protagonist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| CA3167751A1 (en) * | 2020-01-15 | 2021-07-22 | Janssen Biotech, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
-
2022
- 2022-07-14 TW TW111126555A patent/TW202332683A/zh unknown
- 2022-07-14 UY UY0001039856A patent/UY39856A/es unknown
- 2022-07-14 JP JP2024501976A patent/JP2024525780A/ja active Pending
- 2022-07-14 WO PCT/US2022/037221 patent/WO2023288028A2/en not_active Ceased
- 2022-07-14 CA CA3226539A patent/CA3226539A1/en active Pending
- 2022-07-14 US US18/579,062 patent/US20240409598A1/en active Pending
- 2022-07-14 AU AU2022310354A patent/AU2022310354A1/en active Pending
- 2022-07-14 MX MX2024000762A patent/MX2024000762A/es unknown
- 2022-07-14 CN CN202280061973.9A patent/CN117999274A/zh active Pending
- 2022-07-14 KR KR1020247004772A patent/KR20240034222A/ko active Pending
- 2022-07-14 EP EP22842905.6A patent/EP4370531A4/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024525780A5 (https=) | ||
| JP2024525732A5 (https=) | ||
| JP2024525723A5 (https=) | ||
| KR101899803B1 (ko) | 소듐 (2r,5s,13ar)-7,9-디옥소-10-((2,4,6-트리플루오로벤질)카르바모일)-2,3,4,5,7,9,13,13a-옥타히드로-2,5-메타노피리도[1',2':4,5]피라지노[2,1-b][1,3]옥사제핀-8-올레이트 | |
| JP2022540154A5 (https=) | ||
| US11634418B2 (en) | Amino acid compounds and methods of use | |
| US20220135513A1 (en) | Methods of manufacturing treprostinil and treprostinil derivative prodrugs | |
| EP3962602A1 (en) | Itaconic acid derivatives and uses thereof in treating an inflammatory disease or a disease associated with an undesirable immune response | |
| CN1104238C (zh) | 霉酚酸盐的包有肠溶衣的药物组合物 | |
| US10703731B2 (en) | Process for the preparation of Trisodium (4- {[1S,3R)-1-([1,1′-biphenyl]-4-ylmethyl)-4-ethoxy-3-methyl-4-oxobutyl]amino}-4-oxobutanoate)-(N-petanoyl-N-{[2′-(1H-tetrazol-1-1D-5-yl)[1,1′-biphenyl]-4-yl]methyl}- L-valinate) and its polymorphs thereof | |
| TW202332683A (zh) | 介白素－２３受體之肽抑制劑 | |
| JP2023511551A5 (https=) | ||
| TW202321275A (zh) | 介白素—２３受體之雙環肽抑制劑 | |
| JP2023504184A5 (https=) | ||
| CN102264694B (zh) | 用于制备伏立诺他的方法 | |
| CN116710462A (zh) | 用于治疗代谢病症和肝病的组合物和方法 | |
| CN115066418A (zh) | 具有抗炎性质的羧基衍生物 | |
| JP5345065B2 (ja) | デプシペプチドおよびその治療的使用 | |
| JP5731407B2 (ja) | アクタガルジン誘導体 | |
| JP2014511844A5 (https=) | ||
| JP2023513658A5 (https=) | ||
| WO2022090723A1 (en) | Itaconic acid derivatives | |
| WO2016128885A1 (en) | A process for preparation of cobicistat | |
| JP2012524775A5 (https=) | ||
| JP2023538236A5 (https=) |